Hereditary Hemochromatosis Market Overview
Global Hereditary Hemochromatosis Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.
There is an increasing trend of in-hospital admissions of hereditary hemochromatosis patients over the last few years. These trends were likely related to advances in diagnostic approaches, which can lead to increased hospital utilization and cost increments. Also, the development of novel therapies, the increasing adoption of genetic testing for early diagnosis, and the growing focus on personalized medicine. In addition, there is a growing trend towards the use of combination therapies for the treatment of hemochromatosis is expected to dominate the global hereditary hemochromatosis market.
Hemochromatosis is most often caused by a change in a gene. This gene controls the amount of iron in the body which absorbs from food. The altered gene is passed from parents to children. This type of hemochromatosis is by far the most common type.
Furthermore, the hereditary hemochromatosis market is driven by various factors like increased awareness and diagnosis of hemochromatosis disorders, as well as an increase in healthcare spending, Early illness detection and increased financial investment in R&D activities by leading market players will boost the growth of the hemochromatosis treatment market during the forecast period.
Market Scope
| Metrics | Details |
| CAGR | High |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2023-2030 |
| Data Availability | Value (US$) |
| Segments Covered | Type, Treatment Type, Route of Administration, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report Request for Sample
Market Dynamics
Rise in the Prevalence of Hemochromatosis is Expected to Drive the Growth of The Hereditary Hemochromatosis Market
The rise in the prevalence of hemochromatosis is one of the key factors that drives this market during the forecast period. For instance, according to an updated article present in the National Library of Medicine Hereditary hemochromatosis is the most common autosomal recessive disorder in whites, with a prevalence of 1 in 300 to 500 individuals.
Hereditary hemochromatosis types 2, and 3 are seen worldwide but type 1 is mostly seen in people of northern European descent. The prevalence of hemochromatosis is the same in Europe, Australia, and other Western countries with excess in people of Celtic origin. It is less prevalent in patients of African descent. The white population has a six times higher risk of developing the disease than blacks.
A Rise in Awareness About Hemochromatosis Disease is Expected to Drive the Market
A rise in awareness about hemochromatosis will help to detect the disease at early stages, improving patient outcomes and proper utilization of medical resources which helps the overall market to grow during the forecast period. Haemochromatosis or ‘iron overload’ is Ireland’s most common genetic condition.
Early diagnosis is vital and if untreated can lead to organ damage or premature death. The Irish Haemochromatosis Association estimates there are at least 20,000 undiagnosed cases of Haemochromatosis in Ireland.
For instance, in June 2021 the Irish Haemochromatosis Association Launched World Haemochromatosis Awareness Week 1st – 7th June 2021. The main aim behind this is as always, to ensure that as many people as possible know about haemochromatosis, the symptoms, diagnosis and treatment and how to get checked for haemochromatosis.
Increasing Use of Treatment Tests for Overload Iron is Accelerating the Market
An increase in the use of treatment tests for overload iron is also one of the key factors which help the market to accelerate during the forecast period. Serum transferrin saturation tests measure iron levels in the blood, with levels exceeding 45% considered excessive. Ferritin tests determine liver iron storage. Elevations in both tests can be abnormal in adults with hemochromatosis and should be administered after fasting.
Key players in Brazil, India, and China are developing improved distribution channels and manufacturing hubs, driving the hemochromatosis treatment market. The increasing number of pipelines for hemochromatosis treatment pharmaceuticals worldwide fuels market growth.
Complications Associated with Hereditary Hemochromatosis Treatment
Complications associated with Hereditary Hemochromatosis treatment are one of the major factors that hamper the market growth during the forecast period. Some of the complications include Liver problems. Cirrhosis — permanent scarring of the liver, Diabetes. Damage to the pancreas can lead to diabetes., Heart problems, Reproductive problems, Skin colour changes and others.
Market Segment Analysis
The global hereditary hemochromatosis market is segmented based on type, treatment type, route of administration, distribution channel and region.
The Chelation Therapy Segment From The Treatment Segment Accounted For Approximately 41.7% of Hereditary Hemochromatosis Share
The chelation therapy segment from the treatment segment accounted for 41.7% and it is expected to be dominated during the forecast period. Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as the liver and heart after regular transfusion.
For instance, in April 2023, Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced that Health Canada has approved Ferriprox MR deferiprone extended-release tablets 1 000 mg for the treatment of patients with transfusional iron overload due to thalassemia syndromes.
Moreover, in May 2021 Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.P.A. an international research-focused Healthcare Group (Chiesi Group), announced that the U.S. Food & Drug Administration (FDA) has approved FERRIPROX (deferiprone) for the treatment of transfusional iron overload due to sickle cell disease (SCD) or other anaemias in adult and pediatric patients 3 years of age and older. This FDA approval expands the use of FERRIPROX for patients with sickle cell disease or other anaemias as well as patients with thalassemia regardless of prior iron chelation exposure. Thus, the above factors will help the market to grow during the forecast period.
Market Geographical Share
North America Accounted for Approximately 38.4% of the Market Share
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the existence of significant players, product launches, the high frequency of hemochromatosis patients in the region, and the established healthcare infrastructure are some of the primary factors attributed to its significant market share.
Moreover, positive government efforts an increase in the number of research partnerships and advancement in diagnosis procedures of hemochromatosis disease are also expected to fuel market growth. Also, because of growing awareness of the illness, an increasing number of persons with the hemochromatosis gene, and increased birth rates due to genetic variability within the population, the United States has the highest percentage.
For instance, in January 2023 Pharma Science Canada added PRpms-DEFERASIROX (TYPE J) to its product catalogue, available in 90 mg and 360 mg tablets. This medication is used to treat chronic iron overload in adult patients and children aged 6 years and older, children aged 2-5 years who cannot be adequately treated with deferoxamine, and adult patients and children aged 10 years and older with thalassemia syndromes who do not require regular blood transfusions. PRpms-DEFERASIROX (TYPE J) has the same safety and efficacy profile as Jadenu, but is available at a lower cost.
Market Companies
The major global players in the market include Pfizer, Global Calcium, Fresenius Kabi USA, Novartis, Sun Pharma, Teva Pharmaceuticals, Taro Pharmaceuticals, Merck KGaA, Apo Pharma, Livealth Biopharma and among others.
COVID-19 Impact Analysis
Covid 19 had a substantial impact on the global hereditary hemochromatosis market where detrimental impacts iron overload has on viral infections in general and the negative effects of hereditary hemochromatosis on the immune system. Therefore, postulate that the underlying metabolic and immune disturbances seen in hereditary hemochromatosis should be considered a potential risk factor for the development of severe COVID-19. This case also adds to the evidence that hyperinflammation appears to be a unique and interesting characteristic of this novel viral disease.
Also, severe COVID-19 in this patient unmasked underlying hemochromatosis due to elevation in ferritin secondary to acute viral infection. Reporting cases like this will help understand the effect of COVID-19 on underlying iron overload diseases.
Key Developments
- In August 2022, Disc Medicine and Gemeini Therapeutics Inc. merged to create a NASDAQ-listed, clinical-stage biopharmaceutical company focused on expanding Disc’s portfolio of haematology programs. The Hematology portfolio includes a Matriptase-2 inhibitor research program. The therapeutic role of hepcidin has been established in hereditary hemochromatosis patients and it’s being studied for the treatment of diseases associated with iron overload.
- In January 2022 Bond Biosciences closed Series B financing to accelerate manufacturing timelines for BBI-001 and pipeline development. The BBI-001 is an investigational new drug which is initially developed to treat iron overload associated with Hereditary Hemochromatosis. This recent development is expected to strengthen the development program for BBI-001 and advance the pipeline of non-absorbed oral therapies, claims the company.
- In November 2021, Protagonist Therapeutics announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH). HH is a genetic disorder arising from a deficiency or dysregulation of the natural hormone hepcidin, a condition that causes the body to absorb too much iron. The clinical data from the study were presented in an oral presentation at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD).
Why Purchase the Report?
- To visualize the global hereditary hemochromatosis market segmentation based on type, treatment type, route of administration, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global hereditary hemochromatosis market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global hereditary hemochromatosis market report would provide approximately 61 tables, 58 figures and 186 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
